Şeyma Karatekin

Dr. Şeyma Karatekin

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2023 in Namık Kemal Tıp Dergisi
Verified
Journal Article
Closed access
ESEbru Senol
Ebru Senol
AYAysegul Yildirim
Aysegul Yildirim
ŞKŞeyma Karatekin
Şeyma Karatekin

18 March 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
ŞKŞeyma Karatekin
Şeyma Karatekin
STSelda Hançerli Törün
Selda Hançerli Törün
ESEbru Senol
Ebru Senol
SÇSalih Çağrı Çakır
Salih Çağrı Çakır
GGGülbin Gökçay
Gülbin Gökçay
Pertussis is an important cause of mortality and morbidity in infancy. It is recommended that close contacts of the baby be vaccinated with Tdap, and this practice is called the cocoon strategy. This study aimed to investigate the applicability of the cocoon strategy and to determine the factors affecting the process. Mothers of babies who were hospitalized in the neonatal intensive care unit were included in the study. In the first stage, a face-to-face questionnaire was given to the mothers to measure their level of knowledge about whooping cough and its vaccine. In the second stage, written and verbal information about the cocoon strategy was given, and then vaccination intentions for Tdap were learned. In the third stage, all mothers were contacted 3 weeks after and asked whether they had received a Tdap vaccination and why. Of these mothers, 68% could not answer any questions about pertussis disease and vaccines correctly. After the information, 35% (n = 78) of the mothers stated that they were considering getting vaccinated, while only 2% (n = 5) of the mothers were able to get the Tdap vaccine. The most important reasons for not getting vaccinated were a lack of time (24%) and the cost of vaccination (23%). It is predicted that Tdap vaccination rates may increase if the cost of vaccine, availability of vaccine, and the access of mothers to the vaccine application are facilitated.

15 December 2022 in Namık Kemal Tıp Dergisi
Verified
Journal Article
Closed access
ŞKŞeyma Karatekin
Şeyma Karatekin
SÇSalih Çağrı Çakır
Salih Çağrı Çakır
RKRabia Kefeli̇
Rabia Kefeli̇

13 June 2019 in Journal of Pediatric Infection
Verified
Journal Article
Closed access
EBEzgi Bayrakdaroğlu
Ezgi Bayrakdaroğlu
ŞKŞeyma Karatekin
Şeyma Karatekin
IKİlknur Kurt
İlknur Kurt
RŞRengin Şiraneci
Rengin Şiraneci
TYTarık Yıldırım
Tarık Yıldırım
KDKAZIM OKAN DOLU
KAZIM OKAN DOLU


1 June 2025 in Breastfeeding Medicine
Verified
Journal Article
Closed access
ŞKŞeyma Karatekin
Şeyma Karatekin
ESEbru Senol
Ebru Senol
Background: Usage of some medications while breastfeeding is supported with many clinical studies and proven to be safe for the mother-infant dyad, whereas knowledge on many medications' safety depends on pharmacokinetic data that are supported with only case series of real-life results. As data on rosuvastatin usage are limited, we present our case report with safe use of rosuvastatin in a breastfeeding mother of a 13-month-old infant. Case: Pretreatment assessments of the infant were performed. Complete blood count, kidney, and liver function tests were normal. The infant's lipid profile was evaluated before starting the mother's treatment, at 1 month of treatment, and at the fifth month of treatment in which the infant reached 18 months of age. All three evaluations resulted in normal ranges. At the 18-month follow-up of the infant of breastfeeding mother using rosuvastatin, no issues were detected in the child's development. Conclusions: In order for mothers with hypercholesterolemia not to neglect their own treatment while continuing to breastfeed, case reports should be included in the literature. In this case, it was shown that rosuvastatin treatment given to the mother did not affect the lipid profile and neurological development of the baby.